NASDAQ: EUDAEuda Health Holdings Ltd Stock
$1.65-0.21 (-11.29%)
Updated Sep 3, 2025
EUDA Price
$1.65
Fair Value Price
-$0.80
Market Cap
$61.30M
52 Week Low
$1.65
52 Week High
$6.30
P/E
-3.51x
P/B
-24.01x
P/S
36.22x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.01M
Earnings
-$15.36M
Gross Margin
19%
Operating Margin
-381.87%
Profit Margin
-382.9%
Debt to Equity
-1.67
Operating Cash Flow
-$2M
Beta
-0.08
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
EUDA Overview
8i Acquisition 2 Corporation is a "blank check" company formed to effect mergers, stock purchases, or similar combinations with one or more businesses. It targets companies in Asia. 8i Acquisition 2 was incorporated in 2021 and is headquartered in Singapore.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine EUDA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Health Information Service
Industry Rating
A
EUDA
Ranked#30 of 43
Ranked#30 of 43
Be the first to know about important EUDA news, forecast changes, insider trades & much more!
EUDA News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how EUDA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EUDA ($1.65) is overvalued by 306.69% relative to our estimate of its Fair Value price of -$0.80 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
EUDA ($1.65) is not significantly undervalued (306.69%) relative to our estimate of its Fair Value price of -$0.80 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
EUDA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more EUDA due diligence checks available for Premium users.
Valuation
EUDA fair value
Fair Value of EUDA stock based on Discounted Cash Flow (DCF)
Price
$1.65
Fair Value
-$0.80
Undervalued by
306.69%
EUDA ($1.65) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
EUDA ($1.65) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
EUDA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
EUDA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.51x
Industry
84.45x
Market
35.01x
EUDA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-24.01x
Industry
4.03x
EUDA's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
EUDA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
EUDA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.7M
Liabilities
$4.3M
Debt to equity
-1.67
EUDA's short-term liabilities ($4.14M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EUDA's short-term assets ($762.88k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EUDA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
EUDA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
EUDA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
EUDA vs Health Information Service Stocks
Euda Health Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.